Policy & Regulation
I-Mab to expand ongoing phase II and III clinical trials of TJ202/MOR202 into China under fast-to-market development strategy
14 October 2019 - German biopharma company MorphoSys AG (FSE:MOR) (Nasdaq:MOR) stated that I-Mab Biopharma has received Investigational New Drug (IND) clearances from the National Medical Products Adm...
Alexion Pharmaceuticals signs agreement with Stealth BioTherapeutics
14 October 2019 - United States-based Alexion Pharmaceuticals has signed a contract with United States-based Stealth BioTherapeutics.It was reported on Friday that the contract has been signed for an ...
UCB to acquire Ra Pharmaceuticals
14 October 2019 - UCB, a Belgium-based biopharmaceutical firm, has agreed to acquire Ra Pharmaceuticals, a United States-based clinical-stage biopharmaceutical company, it was reported on Friday.The d...
Gilead Sciences and Galapagos NV reveal Week 52 data from the registrational Phase three FINCH 1 and FINCH 3 trials of filgotinib
14 October 2019 - United States-based Gilead Sciences and Belgium-based Galapagos NV have revealed the Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investi...
Gilead Sciences Names Parsey as Chief Medical Officer
11 October 2019 - - US-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) has hired Merdad Parsey, MD, PhD as chief medical officer, effective November 1, the company said.
Acadia Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress
11 October 2019 - - US-based Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) said that, based on secondary analyses from its Phase 2 CLARITY study, adjunctive pimavanserin showed the potential to improve s...